Hematology and Oncology Resources for Healthcare Professionals
At Children's Hospital Colorado, we're committed to helping all healthcare professionals improve the quality of life for children with cancers and blood disorders. Get the latest in hematology and oncology information to better your practice and learn about innovation within our various programs.
These referral guidelines provide useful information to assist referring physicians in the evaluation and management of pediatric patients. Use these to help determine the best approach to the treatment of your patients, or to help determine when to refer to a specialist.
Hematology referral guidelines (.pdf)
Research articles and summaries
Our Youth and Pet Survivors Program (YAPS) matches pediatric cancer patients with animal “pen pals.”
The goal of the study is to identify biologically rational therapeutics for the medical treatment of adamantinomatous craniopharyngioma by confirming the overexpression of specific molecules and ultimately improving treatment for patients with this rare tumor.
- Patients with the diagnosis or clinical suspicion of craniopharyngioma in whom planned clinical management will include tissue sampling
- 0-21 years of age
Charting Pediatrics is a weekly podcast for pediatric healthcare providers. In this series, specialists from Children’s Hospital Colorado examine the latest treatments for the most common complaints in pediatric medicine. Listen and subscribe on Spotify, iTunes and Google Play.
CAR-T Cellular Therapy for Leukemia
In this episode, Terry Fry, MD, and Mike Verneris, MD, explore the topic of cellular therapy for the treatment of pediatric cancers.
Vascular Malformations in Pediatric Primary Care
In this episode, Taizo Nakano, MD, Medical Director of the Vascular Anomalies Center at Children's Colorado, discusses the most common vascular anomalies in the primary care setting.
Hematology and Oncology news
January 23, 2019
Among children with SCA requiring chronic transfusion because of persistently elevated TCD velocities, MSD-HSCT was significantly associated with lower TCD velocities at 1 year compared with standard care. Further research is warranted to assess the effects of MSD-HSCT on clinical outcomes and over longer follow-up.
Journal of Clinical Oncology
January 22, 2019
MRD-stratified treatments improved the outcome for children with hypodiploid ALL. Allogeneic transplantation did not significantly improve outcome overall and, in particular, for patients who achieved MRD-negative status after induction.
January 3, 2019
In this study, pediatric patients with early-stage HL receiving CMT experienced improved overall survival 5 years after treatment. There is a nationwide decrease in the use of CMT, perhaps reflecting the bias of ongoing clinical trials designed to avoid consolidation radiotherapy. This study represents the largest data set to date examining the role of CMT in pediatric HL.